Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis
The FEBS Journal · 2025-08 · 292 (16) · 4160-4182
DOI: 10.1111/febs.17403 ↗Kurz gefasst
Fachartikel in der Zeitschrift The FEBS Journal, online erschienen am 16.01.2025. Verfasst von Sergio Oddi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Medicine, University of Teramo, Italy. Hauptthemen laut MEDLINE: Alzheimer Disease, Amidohydrolases, Amyloidosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Ministero dell'Università e della Ricerca.
Themen: Demenz
Abstract (Originalsprache)
The endocannabinoid N ‐arachidonoylethanolamine (AEA) is a pro‐homeostatic bioactive lipid known for its anti‐inflammatory, anti‐oxidative, immunomodulatory, and neuroprotective properties, which may contrast/mitigate Alzheimer's disease (AD) pathology. This study explores the therapeutic potential of targeting fatty acid amide hydrolase (FAAH), the major enzyme degrading AEA, in mouse models of amyloidosis (APP/PS1 and Tg2576). Enhancing AEA signaling by genetic deletion of FAAH delayed cognitive deficits in APP/PS1 mice and improved cognitive symptoms in 12‐month‐old AD‐like mice. Chronic pharmacological FAAH inhibition fully reverted neurocognitive decline, attenuated neuroinflammation, and promoted neuroprotective mechanisms in Tg2576 mice. Additionally, pharmacological FAAH inhibition robustly suppressed β‐amyloid production and accumulation, associated with decreased expression of β‐site amyloid precursor protein cleaving enzyme 1 (BACE1), possibly through a cannabinoid receptor 1‐dependent epigenetic mechanism. These findings improve our understanding of AEA signaling in AD pathogenesis and provide proof of concept that selective targeting of FAAH activity could be a promising therapeutic strategy against AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Medicine, University of Teramo, Italy.
- European Center for Brain Research/Institute for Research and Health Care (IRCCS) Santa Lucia Foundation, Rome, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Italy.
- Department of Pharmacy - Pharmaceutical Sciences, University of Bari "Aldo Moro", Bari, Italy.
- Department of Medicine, Campus Bio-Medico University of Rome, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
ORCID-Profile: Sergio Oddi, Francesca Ciaramellano
Förderung
- Ministero dell'Università e della Ricerca
Zitieren
APA
Oddi, S., Scipioni, L., Totaro, A., Giacovazzo, G., Ciaramellano, F., Tortolani, D., Leuti, A., Businaro, R., Armeli, F., Bilkei-Gorzo, A., Coccurello, R., Zimmer, A., & Maccarrone, M. (2025). Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis. The FEBS Journal, 292(16), 4160-4182. https://doi.org/10.1111/febs.17403
Vancouver
Oddi S, Scipioni L, Totaro A, Giacovazzo G, Ciaramellano F, Tortolani D, et al. Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis. The FEBS Journal. 2025;292(16):4160-4182. doi:10.1111/febs.17403
BibTeX
@article{Oddi2025,
author = {Oddi, Sergio and Scipioni, Lucia and Totaro, Antonio and Giacovazzo, Giacomo and Ciaramellano, Francesca and Tortolani, Daniel and Leuti, Alessandro and Businaro, Rita and Armeli, Federica and Bilkei-Gorzo, Andras and Coccurello, Roberto and Zimmer, Andreas and Maccarrone, Mauro},
title = {Fatty‐acid amide hydrolase inhibition mitigates Alzheimer's disease progression in mouse models of amyloidosis},
journal = {The FEBS Journal},
year = {2025},
volume = {292},
number = {16},
pages = {4160--4182},
doi = {10.1111/febs.17403}
}
EUVIMED